10-Q: INmune Bio Faces Alzheimer's Setback, Pursues New Funding

INmune Bio reported a significant net loss and going concern doubt, driven by a failed Alzheimer's trial and a substantial asset impairment, despite progress in other programs and recent capital raises.

Summary

• INmune Bio reported a net loss of $40.7 million for the nine months ended September 30, 2025, compared to $32.9 million for the same period in 2024.
• The Phase 2 clinical trial for its Alzheimer's drug candidate, XPro, failed to meet its primary and key secondary endpoints in the modified intent-to-treat population.
• A prespecified subgroup analysis for XPro showed trends toward improvement in patients with both amyloid positivity and higher inflammation, with effect sizes of 0.27 for EMACC and -0.23 for NPI.
• The company recorded a $16.5 million impairment of acquired in-process research and development intangible assets related to XPro due to insufficient resources to fund further trials and the decision to seek a partner.
• Cash and cash equivalents increased to $27.7 million as of September 30, 2025, from $20.9 million at December 31, 2024, primarily due to recent equity financings.
• Net cash used in operating activities improved to $19.6 million for the nine months ended September 30, 2025, from $22.3 million in the prior year period.
• The CORDStrom program for recessive dystrophic epidermolysis bullosa (RDEB) showed positive top-line results from the MissionEB study, demonstrating reduced itch scores and improved skin integrity.
• CORDStrom received Rare Pediatric Disease Designation (RPDD) on December 13, 2024, and Orphan Drug Designation (ODD) on January 6, 2025, from the FDA.
• The INKmune Phase I trial for high-risk MDS/AML was terminated in March 2024 due to recruitment issues, but a Phase I/II trial for metastatic castrate-resistant prostate cancer is ongoing and expected to complete enrollment in Q4 2025.
• The company has raised $17.4 million net from a registered direct offering in June 2025 and $10.1 million net from an At-The-Market (ATM) offering during the nine months ended September 30, 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the primary endpoint failure of the lead Alzheimer's drug candidate (XPro), the significant asset impairment, and the explicit 'going concern' warning. While there are positives like the CORDStrom program's progress and recent capital raises, the core financial instability and major clinical setback for XPro weigh heavily on the overall outlook.

Positives

• The CORDStrom program for RDEB demonstrated positive clinical benefits in the MissionEB study, including significant and sustained reduction in itch scores and improved skin integrity in pediatric patients.
• CORDStrom received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the FDA, which could lead to a Priority Review Voucher and market exclusivity.
• Cash and cash equivalents increased to $27.7 million as of September 30, 2025, from $20.9 million at December 31, 2024, providing some liquidity.
• Net cash used in operating activities decreased to $19.6 million for the nine months ended September 30, 2025, from $22.3 million in the prior year, indicating a reduced operational cash burn.
• A prespecified subgroup in the XPro Alzheimer's trial showed trends toward improvement on key cognitive and neuropsychiatric endpoints, suggesting potential for a targeted patient population.
• The INKmune therapy was determined to be safe and promotes the development of cancer-killing memory-like NK cells, despite the termination of the MDS/AML trial.

Negatives

• The XPro Phase 2 clinical trial for Alzheimer's disease failed to meet its primary and key secondary endpoints in the overall modified intent-to-treat population.
• A significant impairment charge of $16.5 million was recorded for acquired in-process research and development intangible assets related to XPro, reflecting a halt in immediate development plans due to insufficient resources.
• The company incurred a higher net loss of $40.7 million for the nine months ended September 30, 2025, compared to $32.9 million in the prior year.
• The company has incurred significant losses and negative cash flows from operations since inception and projects insufficient liquidity to sustain operations through one year, raising substantial doubt about its ability to continue as a going concern.
• The Phase I trial for INKmune in high-risk MDS/AML was terminated due to post-Covid recruitment problems, limiting data from that indication.
• Part 2 of the MissionEB study for CORDStrom is uninitiated due to a lack of funding by the National Health Services England (NHSE).

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses and negative cash flows from operations.
• Inability to secure additional financing through equity, debt, collaborations, or licensing arrangements on favorable terms could force the company to delay, scale back, or discontinue product development or cease operations.
• The XPro Alzheimer's drug candidate failed its primary endpoint in Phase 2, and future development is contingent on finding a partner and securing additional funding.
• Product candidates are still in development and require significant additional R&D, clinical trials, and regulatory approval, with no assurance of successful commercialization or revenue generation.
• The company operates in a highly competitive biotechnology industry with rapid technological change and competition from larger companies.
• Dependence on a small number of vendors for manufacturing supplies and materials for clinical trial programs poses a risk of significant interruption.
• Fluctuations in foreign currency exchange rates (USD, GBP, AUD) could adversely affect financial results, particularly R&D expenses incurred in Australia and the UK.
• The MissionEB study's Part 2 for CORDStrom is uninitiated due to a lack of funding, which could delay further data generation or commercialization efforts.

Future Outlook

The company plans an end-of-phase 2 meeting with the FDA for XPro by late 2025 or early 2026 to determine next steps and explore accelerated pathways, while actively seeking a partner for further XPro development. For CORDStrom, the company intends to submit a Biologics License Application (BLA) to the FDA this year (2025) and Marketing Authorization Applications (MAAs) to the EU and UK in 2026. The INKmune Phase I/II trial for metastatic castrate-resistant prostate cancer is expected to complete enrollment in Q4 2025, with top-line data anticipated approximately six months thereafter. The company expects to continue incurring significant losses and increasing operating expenses as it advances product candidates and seeks regulatory approvals.

Management Comments

• Management believes the findings from the XPro Phase 2 results indicate that XPro may offer benefits to a readily identified subgroup of Alzheimer's patients across all ages with biomarker-defined neuroinflammation, regardless of comorbidities or ApoE4 status, potentially laying the foundation for advancing XPro as a promising treatment for AD.
• Management is currently evaluating different strategies to obtain the required funding of future operations, including public or private sale of equity, debt financings, government funding, collaborations, strategic alliances, divestment of non-core assets, or licensing arrangements with third parties.
• Management believes the CORDStrom product platform shares many similarities with the INKmune oncology product, enabling the company to leverage economies of scale, experienced staff, and other resources for efficient manufacturing of both products.

Industry Context

The biotechnology industry faces high risks and significant capital requirements for drug development, particularly in complex areas like Alzheimer's disease, where clinical trial failures are common. The positive results and regulatory designations for CORDStrom in RDEB highlight the potential for orphan drugs, which often benefit from accelerated pathways and market exclusivity due to unmet medical needs. The company's strategy of seeking partnerships for high-cost programs like XPro is a common approach in biotech to de-risk development and share financial burdens. The ongoing INKmune trial reflects continued efforts in the competitive oncology space, focusing on novel immune-modulating therapies.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Settled a dispute with a vendor for approximately $0.2 million during August 2025, where the vendor had invoiced approximately $1.6 million for services.

Related Party Transactions

• Payments of $132,000 (9 months ended Sep 30, 2025) to UCL for medical research, where the company's Chief Scientific and Manufacturing Officer is a professor at the University of London (UCL's parent).
• A payable of $25,000 to Immune Ventures for INKmune Phase I initiation, where the company's CEO, CSO, and former CEO are owners of Immune Ventures.
• A payable of $26,000 to AmplifyBio as of September 30, 2025, where AmplifyBio's former CEO is on the company's board of directors. AmplifyBio ceased operations during 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and significant uncertainty regarding the company's ability to continue as a going concern, which could negatively impact share price.
• Patients with Alzheimer's disease who were hopeful for XPro may experience disappointment due to the Phase 2 trial failure and the halt in immediate development plans.
• Patients with RDEB and their caregivers may benefit from the positive CORDStrom clinical results and the company's plans for regulatory submissions, offering hope for a new treatment option.
• Employees may face uncertainty given the company's financial challenges and the mention of additional compensation expense mainly due to costs associated with the termination of employees.
• Creditors and suppliers may face increased risk due to the company's going concern warning and reliance on future financing.

Next Steps

• Plan and hold an end-of-phase 2 meeting with the FDA for XPro by late 2025 or early 2026 to determine next steps and eligibility for accelerated pathways.
• Seek a partner to continue development of XPro for Alzheimer's or other indications.
• Prepare for and hold a pre-BLA meeting with the FDA for CORDStrom.
• Submit a Biologics License Application (BLA) to the FDA for CORDStrom for RDEB treatment this year (2025).
• Submit Marketing Authorization Applications (MAAs) to the EU and United Kingdom for CORDStrom in 2026.
• Complete enrollment in the INKmune Phase I/II trial for metastatic castrate-resistant prostate cancer during the fourth quarter of 2025.
• Anticipate top-line data from the INKmune mCRPC trial approximately six months after full enrollment.
• Continue evaluating and pursuing financing strategies to obtain required funding for future operations and address going concern issues.

Key Dates

Recommendation

The filing presents a mixed bag of significant challenges and promising developments. The failure of the XPro Alzheimer's trial to meet its primary endpoint and the subsequent $16.5 million impairment are major setbacks, contributing to a substantial net loss and raising 'going concern' doubts. This indicates high financial risk and a need for further capital. However, the CORDStrom program shows strong positive clinical results in a rare pediatric disease, backed by FDA designations (RPDD, ODD), and is on an accelerated path to BLA submission. The company has also successfully raised capital recently, improving its cash position in the short term. For a seasoned investor, the stock is highly speculative. A 'hold' recommendation acknowledges the severe risks associated with the XPro failure and going concern, but also recognizes the significant potential of the CORDStrom asset and the ongoing efforts to secure financing and advance other programs. Investors should closely monitor progress on CORDStrom's regulatory path and the company's ability to secure a partner for XPro and additional funding.

Keywords

Biotechnology, Alzheimer's Disease, XPro1595, DN-TNF, Recessive Dystrophic Epidermolysis Bullosa, RDEB, CORDStrom, Natural Killer Cell Priming, INKmune, Oncology, Prostate Cancer, Clinical Trials, SEC Filing, 10-Q, Biopharmaceutical, Neuroinflammation, Orphan Drug, Rare Pediatric Disease, Going Concern, Capital Raise